“Breaking New Ground in Parathyroid Hormone-Related Treatments”

Speaker:

Michael Mannstadt, M.D.
Chief of the Endocrine Unit
Associate Professor in Medicine, Harvard Medical School
Massachusetts General Hospital

About Michael Mannstadt:

Dr. Mannstadt earned his medical degree from Jena University in Germany. He then completed internal medicine residency training, followed by a clinical fellowship in endocrinology, diabetes and metabolism, at Massachusetts General Hospital and Harvard Medical School. 

Dr. Mannstadt's clinical interests include disorders of mineral metabolism and bone diseases. His research concentrates on the basic and translational aspects of parathyroid hormone with a particular interest in hypoparathyroidism. 

He is a Board Certified Endocrinologist who serves as Chief of the Endocrine Unit at Massachusetts General Hospital and Associate Professor in Medicine, Harvard Medical School, both in Boston.

Dr. Mannstadt established his laboratory within the Endocrine Unit of Massachusetts General Hospital. His research focuses on parathyroid function and disease including (1) understanding the genetic basis of familial hypoparathyroidism; (2) defining the mechanisms by which the newly identified genes and pathways impact parathyroid function; (3) using these insights to improve treatment for parathyroid disorders. His basic research also investigates the transcriptional network of parathyroid cells. His clinical research focuses in particular on hypoparathyroidism and his research group analyzed one of the largest patient series in hypoparathyroidism. This study reveals significant shortcomings of our current therapy. Recognizing the limitations of current therapies, he became the Principal Investigator of an NIH grant for the development of a long-acting PTH, and is the lead author of the phase 3 clinical trial of PTH(1-84) in hypoparathyroidism. He is a Medical Advisor for the Hypoparathyroid Association and a frequent faculty participant at their annual patient meetings. He has participated in the development of guidelines for the management of hypoparathyroidism. 

Visit the Mannstadt Lab